Chengdu Kanghong Pharmaceutical Group Co., Ltd
SZSE:002773.SZ
15.14 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,957.46 | 3,389.028 | 3,605.347 | 3,295.43 | 3,257.43 | 2,917.445 | 2,786.497 | 2,540.032 | 2,074.352 | 1,674.519 | 1,476.628 | 1,331.374 | 1,016.533 | 796.088 | 638.21 |
| Cost of Revenue
| 438.844 | 388.035 | 354.606 | 329.737 | 263.849 | 228.505 | 269.292 | 243.619 | 225.502 | 193.49 | 171.313 | 156.976 | 114.951 | 84.019 | 67.396 |
| Gross Profit
| 3,518.615 | 3,000.993 | 3,250.741 | 2,965.693 | 2,993.581 | 2,688.94 | 2,517.205 | 2,296.412 | 1,848.85 | 1,481.029 | 1,305.315 | 1,174.398 | 901.581 | 712.069 | 570.814 |
| Gross Profit Ratio
| 0.889 | 0.886 | 0.902 | 0.9 | 0.919 | 0.922 | 0.903 | 0.904 | 0.891 | 0.884 | 0.884 | 0.882 | 0.887 | 0.894 | 0.894 |
| Reseach & Development Expenses
| 421.678 | 373.998 | 1,008.365 | 1,676.068 | 286.943 | 230.366 | 191.933 | 122.233 | 99.389 | 75.497 | 59.57 | 47.02 | 0 | 0 | 0 |
| General & Administrative Expenses
| 166.444 | 149.243 | 162.096 | 290.03 | 212.598 | 229.772 | 192.507 | 178.973 | 125.257 | 120.96 | 130.73 | 124.122 | 192.602 | 169.41 | 153.918 |
| Selling & Marketing Expenses
| 843.3 | 1,320.234 | 1,403.622 | 1,406.751 | 1,567.507 | 1,375.623 | 1,276.995 | 1,345.462 | 1,097.973 | 870.947 | 713.095 | 651.331 | 486.366 | 389.003 | 298.28 |
| SG&A
| 1,943.29 | 1,469.478 | 1,565.718 | 1,696.781 | 1,780.105 | 1,605.395 | 1,469.502 | 1,524.434 | 1,223.23 | 991.907 | 843.825 | 775.452 | 678.967 | 558.413 | 452.199 |
| Other Expenses
| -107.421 | 221.256 | 168.965 | 166.935 | 157.515 | 3.253 | -24.466 | 16.723 | 21.629 | 9.831 | 19.861 | 32.843 | 27.529 | 13.902 | 0.182 |
| Operating Expenses
| 2,257.548 | 2,064.731 | 2,743.048 | 3,539.784 | 2,224.562 | 1,962.392 | 1,755.812 | 1,778.227 | 1,437.083 | 1,169.403 | 1,007.231 | 916.208 | 695.98 | 570.82 | 462.175 |
| Operating Income
| 1,261.068 | 1,015.368 | 606.69 | -574.091 | 820.753 | 796.204 | 787.53 | 556.739 | 437.815 | 329.562 | 352.873 | 219.131 | 178.316 | 123.758 | 103.99 |
| Operating Income Ratio
| 0.319 | 0.3 | 0.168 | -0.174 | 0.252 | 0.273 | 0.283 | 0.219 | 0.211 | 0.197 | 0.239 | 0.165 | 0.175 | 0.155 | 0.163 |
| Total Other Income Expenses Net
| -27.151 | 14.929 | 38.243 | -7.225 | 14.427 | 3.253 | -24.466 | 16.526 | 18.568 | 8.056 | 19.552 | -7.32 | 27.067 | 13.558 | -0.156 |
| Income Before Tax
| 1,233.917 | 1,030.296 | 393.42 | -519.513 | 835.179 | 799.457 | 763.064 | 567.753 | 456.383 | 337.617 | 372.425 | 250.87 | 205.382 | 137.316 | 103.834 |
| Income Before Tax Ratio
| 0.312 | 0.304 | 0.109 | -0.158 | 0.256 | 0.274 | 0.274 | 0.224 | 0.22 | 0.202 | 0.252 | 0.188 | 0.202 | 0.172 | 0.163 |
| Income Tax Expense
| 202.793 | 164.485 | -27.66 | -249.66 | 116.989 | 104.513 | 118.865 | 67.633 | 59.397 | 61.152 | 53.295 | 45.092 | 37.715 | 28.809 | 21.387 |
| Net Income
| 1,044.766 | 896.67 | 421.084 | -269.853 | 718.19 | 694.944 | 644.199 | 496.752 | 393.813 | 273.482 | 315.713 | 202.746 | 165.026 | 108.507 | 82.447 |
| Net Income Ratio
| 0.264 | 0.265 | 0.117 | -0.082 | 0.22 | 0.238 | 0.231 | 0.196 | 0.19 | 0.163 | 0.214 | 0.152 | 0.162 | 0.136 | 0.129 |
| EPS
| 1.14 | 0.98 | 0.46 | -0.29 | 0.82 | 0.8 | 0.74 | 0.57 | 0.48 | 0.35 | 0.4 | 0.26 | 0.22 | 0.17 | 0.13 |
| EPS Diluted
| 1.14 | 0.98 | 0.46 | -0.29 | 0.82 | 0.8 | 0.73 | 0.57 | 0.48 | 0.35 | 0.4 | 0.26 | 0.22 | 0.17 | 0.13 |
| EBITDA
| 1,388.659 | 1,094.534 | 545.896 | -396.426 | 932.087 | 881.571 | 836.222 | 640.018 | 528.463 | 407.834 | 384.272 | 342.104 | 236.302 | 168.205 | 131.021 |
| EBITDA Ratio
| 0.351 | 0.324 | 0.21 | -0.122 | 0.265 | 0.276 | 0.309 | 0.251 | 0.253 | 0.244 | 0.293 | 0.231 | 0.235 | 0.218 | 0.207 |